An interventional study of Topical metformin 30% cream and Placebo in Psoriasis Vulgaris, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Psoriasis by Cairo University — 6 open to participants now, 6 under way, 1 of them phase 3. Psoriasis · Cairo University.
Among the 22 studies in Psoriasis by Cairo University, this one is the 5th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2026, is one of 13 with no phase, and was the 19th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →6 of the 22 studies in Psoriasis by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 35–45 · Women only
Cairo University · Sites in Egypt
Ages 45–55
Cairo University
Cairo University · Sites in Egypt
Ages 18+
Cairo University · Sites in Egypt
Ages 18–60
By country, each count listing its studies:
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 2 · Phase 4 4
First in 2010; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 55 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 40 across the 20 interventional studies, 214 across the 2 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
3 of the studies in Psoriasis by Cairo University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07892339Phase 3Cairo UniversityEfficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. | 2026-12-13 |
| NCT07919873Cairo UniversityEfficacy of Fractional Co2 Laser With Topical Tacrolimus 0.1 in the Treatment of Nail Psoriasis | 2027-02 |
| NCT07713212Cairo UniversityCombined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis | 2027-02-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Psoriasis by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if topical metformin works to treat mild psoriasis vulgaris. It will also learn about the safety of topical metformin. The main questions it aims to answer are:
Does topical metformin improve psoriatic plaques in early psoriasis? What medical problems do participants have when use topical metformin? Researchers will compare topical metformin to a placebo (a look-alike substance that contains no drug) to see if topical metformin works to treat psoriasis vulgaris.
Participants will:
put topical metformin or placebo twice daily for 2 months. Visit the clinic once every months for follow up. Keep a diary of their symptoms and any side effects.
Skin biopsy will be taken from psoriatic plaque before starting treatment and another one will be taken after 2 months of starting treatment to assess the level of IL-17.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patient with mild psoriasis with PASI less than 10% will receive topical metformin 30% cream twice daily
Drug: Topical metformin 30% cream
patients with mild psoriasis vulgaris will receive placebo cream twice daily
Drug: Placebo
Metformin 30% loaded cream will be prepared using stearic acid as a lipid phase for group 1.
a plain similar cream (without metformin) will be prepared as a placebo.
Assessment and comparison of tissue levels of interleukin 17 (IL - 17) between the topical metformin and placebo group.
Time frame: 8 weeks after starting treatment
Comparison of percent PASI improvement from baseline between the topical metformin and placebo groups.
Time frame: 8 weeks after starting treatment
Comparison of percentage of patients who achieved ≥4-point improvement from baseline worst itch numeric rating score (WI- NRS) between the topical metformin and placebo groups.
Time frame: 8 weeks after starting treatment
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Jul 2026, 3 months later.
Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 3 months is below that.
Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin